Figure 1 shows significantly higher sSIGLEC5 levels in patients with CRC (n = 114) compared with HVs (n = 67) (p ≤ 0.0001). Note exitus patients (in red) show the highest values of sSIGLEC5. On the other hand, other soluble ICs (sPD-1 and sPD-L1) commonly assayed for CRC immunotherapies did not show significant differences in plasma concentration between the patients with CRC (n = 114) and randomly chosen HVs (n = 30), as shown in Figure S1. The gene discussed is SPDL1; the disease is colorectal carcinoma.